Thymidine Kinase 1 Upregulation is an Early Event in Breast Tumor Formation

Overview

Journal J Oncol

Specialty Oncology

Date 2012 Jul 11

PMID 22778736

Citations 29

Authors

Melissa M Alegre

Richard A Robison

Kim L ONeill

Affiliations

Soon will be listed here.

Abstract

Prognostic markers play an important role in our understanding of tumors and how to treat them. Thymidine kinase 1 (TK1), a proliferation marker involved in DNA repair, has been shown to have independent prognostic potential. This prognostic potential includes the novel concept that upregulation of serum TK1 levels is an early event in cancer development. This same effect may also be seen in tumor tissue. In order to demonstrate that TK1 upregulation is an early event in tumor tissue formation, tissue arrays were obtained and stained for TK1 by immunohistochemistry. Using a progressive breast tissue array, precancerous tissue including breast adenosis, simple hyperplasia, and atypical hyperplasia stained positive for TK1 expression. Different stages of breast carcinoma tissue also stained positive for TK1 including nonspecific infiltrating duct, infiltrating lobular, and infiltrating duct with lymph node metastasis carcinomas. This indicates that TK1 upregulation is an early event in breast carcinoma development, and may be useful in identifying precancerous tissue. Further work is needed to better understand the differences seen between TK1 positive and negative tissues.

Citing Articles

Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization.

Li Z, Wu Z, You X, Tang N Cancer Cell Int. 2024; 24(1):329.

PMID: 39343871 PMC: 11440694. DOI: 10.1186/s12935-024-03515-x.

Structural Characterization of Heat Shock Protein 90β and Molecular Interactions with Geldanamycin and Ritonavir: A Computational Study.

Lima C, Antunes D, Caffarena E, Carels N Int J Mol Sci. 2024; 25(16).

PMID: 39201468 PMC: 11354266. DOI: 10.3390/ijms25168782.

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.

Haller S, Essani K Biomedicines. 2024; 12(8).

PMID: 39200298 PMC: 11351728. DOI: 10.3390/biomedicines12081834.

TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.

Bitter E, Skidmore J, Allen C, Erickson R, Morris R, Mortimer T PLoS One. 2023; 18(11):e0293128.

PMID: 38033034 PMC: 10688958. DOI: 10.1371/journal.pone.0293128.

Methylation status of TK1 correlated with immune infiltrates in prostate cancer.

Zhang C, Ma S, Hao X, Wang Z, Sun Z Front Genet. 2022; 13:899384.

PMID: 36035114 PMC: 9403003. DOI: 10.3389/fgene.2022.899384.

References

Huang S, Lin J, Guo N, Zhang M, Yun X, Liu S . Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev. 2011; 12(2):497-505. View

Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, Hamburger T . Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010; 7(2):65-72. DOI: 10.3233/CBM-2010-0148. View

Nikolenyi A, Uhercsak G, Csenki M, Hamar S, Csorgo E, Tanczos E . Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy. Pathol Oncol Res. 2011; 18(1):61-8. DOI: 10.1007/s12253-011-9417-4. View

ONeill K, Hoper M, Odling-Smee G . Can thymidine kinase levels in breast tumors predict disease recurrence?. J Natl Cancer Inst. 1992; 84(23):1825-8. DOI: 10.1093/jnci/84.23.1825. View

Mukhtar R, Moore A, Nseyo O, Baehner F, Au A, Moore D . Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011; 130(2):635-44. DOI: 10.1007/s10549-011-1646-4. View

Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J . Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management. Mol Med Rep. 2011; 2(6):923-9. DOI: 10.3892/mmr_00000193. View

Li Z, Wang Y, He J, Ma J, Zhao L, Chen H . Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev. 2010; 19(4):313-8. DOI: 10.1097/CEJ.0b013e32833ad320. View

Gasparri F, Wang N, Skog S, Galvani A, Eriksson S . Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. Eur J Cell Biol. 2009; 88(12):779-85. DOI: 10.1016/j.ejcb.2009.06.005. View

He Q, Mao Y, Wu J, Decker C, Merza M, Wang N . Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol. 2004; 25(4):945-53. View

10.

Votava T, Topolcan O, Holubec Jr L, Cerna Z, Sasek L, Finek J . Changes of serum thymidine kinase in children with acute leukemia. Anticancer Res. 2007; 27(4A):1925-8. View

11.

Hengstschlager M, Pfeilstocker M, Wawra E . Thymidine kinase expression. A marker for malignant cells. Adv Exp Med Biol. 1998; 431:455-60. View

12.

Stuart-Harris R, Caldas C, Pinder S, Pharoah P . Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008; 17(4):323-34. DOI: 10.1016/j.breast.2008.02.002. View

13.

ONeill K, Buckwalter M, Murray B . Thymidine kinase: diagnostic and prognostic potential. Expert Rev Mol Diagn. 2002; 1(4):428-33. DOI: 10.1586/14737159.1.4.428. View

14.

Mao Y, Wu J, Wang N, He L, Wu C, He Q . A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest. 2002; 20(7-8):922-31. DOI: 10.1081/cnv-120005905. View

15.

Foekens J, Romain S, Look M, Martin P, Klijn J . Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res. 2001; 61(4):1421-5. View

16.

Svobodova S, Topolcan O, Holubec L, Treska V, Sutnar A, Rupert K . Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res. 2007; 27(4A):1907-9. View

17.

He Q, Fornander T, Johansson H, Johansson U, Hu G, Rutqvist L . Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res. 2007; 26(6C):4753-9. View

18.

He E, Xu X, Guan H, Chen Y, Chen Z, Pan Z . Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids. 2010; 29(4-6):352-8. DOI: 10.1080/15257771003738535. View

19.

Mikulits W, Hengstschlager M, Sauer T, Wintersberger E, Mullner E . Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem. 1996; 271(2):853-60. DOI: 10.1074/jbc.271.2.853. View

20.

Nisman B, Yutkin V, Nechushtan H, Gofrit O, Peretz T, Gronowitz S . Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010; 76(2):513.e1-6. DOI: 10.1016/j.urology.2010.04.034. View